Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Apixaban in Cerebral Venous Thrombosis
NCT06531122Phase 3Recruiting
- Sponsor
- Kafrelsheikh University
- Start
- Aug 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of rivaroxaban in Cerebral venous thrombosis (CVT) (2 arms), sponsored by Kafrelsheikh University. Primary endpoints: Proportion of subjects who have partial or complete venous recanalization at 180 days and Rate of drug-related hemorrhagic complications at 180 days. Started Aug 2021; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Cerebral venous thrombosis (CVT)
Beyond the preview
Go deeper on NCT06531122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531122.